Avanzando Caminos (Leading Pathways): Design and Procedures of The Hispanic/Latino Cancer Survivorship Study

By sjmartinez • April 5, 2024

Penedo FJ, Moreno PI, Pons M, Pinheiro PS, Antoni MH, Lopes G, Calfa C, Chalela P, Garcini L, Wang CP, Chen Y, Diaz A, Cole S, Ramirez AG. Avanzando Caminos (Leading Pathways): Design and Procedures of The Hispanic/Latino Cancer Survivorship Study. Am J Epidemiol. 2024 Apr 3:kwae033. doi: 10.1093/aje/kwae033. Epub ahead of print. PMID: 38576195.

Tags: Cancer, Hematology/Oncology, Hispanics, Latinos, post-treatment completion, Publications, Quality of Life, survivorship

Related Posts

Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib

Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman[...]

ZNFX1 functions as a master regulator of epigenetically induced pathogen mimicry and inflammasome signaling in cancer

Stojanovic L, Abbotts R, Tripathi K, Coon CM, Rajendran S, Abbasi Farid E, Hostetter G, Guarnieri JW, Wallace DC, Liu S, Wan J, Calendo G,[...]

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka[...]